NCT06860867招募中不适用
A Multi-center Traditional Feasibility Trial of the PerQdisc Artificial Implant in Treatment of Single-level Discogenic Back Pain.
Spinal Stabilization Technologies11 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2025年1月10日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 11
- 主要终点
- Clinical Composite Success
研究概览
简要总结
This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label.
After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.
详细描述
The proposed investigation is a multicenter, prospective, traditional feasibility study of the PerQdisc. A minimum of N=5 subjects will be enrolled. Subjects will be enrolled in approximately 2 sites. Data analyses including all enrolled subjects meeting specific criteria will be submitted to the FDA to support a pivotal trial and used in trial planning. This study will evaluate the safety and effectiveness of the PerQdisc device in the treatment of single level discogenic back pain caused by degenerative disc disease (DDD) (L1 to L5).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Skeletally mature male or female subjects aged 22-70 (inclusive).
- •Subject has a primary diagnosis of single level discogenic back pain caused by degenerative disc disease (L1 to L5) identified via MRI.
- •Subject has an intact annulus (as determined by MRI) and endplates (as determined by MRI and X-ray) at the level to be treated.
- •Subject must have failed to respond to a minimum of 6 months of conservative treatment for their back pain (e.g., physical therapy, medications, injections, ablations, lifestyle changes, etc.).
- •Subject has a low back pain VAS ≥40 mm (4 cm).
- •Subject has adequate disc height (≥6mm measured at the center of the disc) at the level to be treated. [As measured by the investigator]
- •Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
- •Subject has read and understands the IRB approved informed consent document prior to signing and dating the document and before the initiation of any study-related procedures
- •Subject is appropriate candidate for the PerQdisc surgical approach [as defined in the surgical technique guide].
排除标准
- •Subject has symptomatic degenerative disc disease at more than one lumbar level
- •Subject has had a prior spinal fusion in the lumbar or thoracic intervertebral spaces.
- •Subject has had a prior SI-joint fusion.
- •Subject has a spinal cord stimulator.
- •Subject has had any prior lumbar spine surgery (instrumented or non-instrumented)
- •Subject has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
- •Subject has congenital moderate or severe spinal stenosis or epidural lipomatosis.
- •Subject has spondylolisthesis (antero- or retrolisthesis) in static X-ray ≥3 mm [measured via neutral lateral x-ray]
- •Subject has ≥4 mm dynamic spondylolisthesis [measured via flexion/extension x-rays]
- •Subject has > 20 degree range of motion at the index level [measured via flexion/extension x-rays]
- •Subject has a history of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).
- •Subject has an active systemic infection or infection at the operative site.
- •Subject has evidence of symptomatic facet joint degeneration or disease where the investigator feels the facet is a major contributor to the subject's pain as diagnosed by injection and/or imaging.
- •Subject has a known allergy to silicone or barium sulfate.
- •Subject has been diagnosed with fibromyalgia, hepatitis, rheumatoid arthritis, lupus erythematosus, AIDs, ARC, HIV, or an autoimmune disease that affects the musculoskeletal system.
- •Subject has been diagnosed with Paget's disease, osteomalacia or any other metabolic bone disease.
- •Subject has current or recent history (defined ≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) using standard medical definitions of DSM-5
- •Subject has morbid obesity defined as a body mass index (BMI) >
- •Subject participated in an investigational drug or another medical device study within the last 30 days prior to surgery.
- •Subject has Osteoporosis, defined as a T-score ≤ -2.
- •An existing DEXA is allowed if completed within 6 months of subject surgery.
- •For all subjects without an existing DEXA, the SCORE/MORES will be utilized to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required.
- •Female subjects who are pregnant or are trying to become pregnant during the course of the trial.
- •Subject has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
- •Subject belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)
- •Subject is currently receiving worker's compensation or is involved in any litigation for medical negligence, trauma, or worker's compensation.
- •Subject has lumbar scoliosis > 10 degrees at index level.
- •Subject has a large, rectangular or irregularly shaped Schmorl's node with an associated active inflammatory process (Modic I changes).
- •Subject has motion of < 3 degrees on pre-operative lateral flexion/extension radiographs at index level.
- •Subject has opioid medication usage > 60 MME (morphine milligram equivalent)/day or change in opioid prescription within 60 days of surgery.
- •Subject has a preoperative VAS right or left leg pain score > the preoperative VAS Back score.
- •Subject has a history of vertebral fractures in the lumbar spine.
- •Subject has evidence of severe compression of cauda equina.
- •Subject is on chronic anticoagulation therapy due to a bleeding disorder and is unable to safely stop anticoagulants or has taken anticoagulants within 3 days prior to procedure.
- •Subject has low back pain (LBP) of non-spinal or unknown etiology.
- •Subject is unable to undergo X-ray, MRI, or other radiographic assessments, including discography.
- •Subject has a degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to spinal disease (not at index level), Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
- •Subject has, in the opinion of the investigator, a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device.
- •In the opinion of the investigator the subject has a major psychiatric disorder that may interfere with the assessment of the safety or effectiveness of the device.
- •Subject has myelopathy.
- •Subject has primarily leg pain with associated nerve root compression, in the opinion of the investigator.
- •Subject has an annular defect greater than 6mm that extends from the interior of the disc to the outer margin of the annulus as evaluated on MRI.
研究组 & 干预措施
PerQdisc
Experimental
The PerQdisc device is the first in a new category of contained in-situ filled and then cured lumbar spinal implant. The PerQdisc is intended to replace the nucleus pulposus in a single lumbar disc level, preserve motion and alleviate pain. The PerQdisc is a silicone membrane (barrier membrane) configured to be filled with a room temperature vulcanizing silicone (RTVS) that will cure within minutes, resulting in a final shape that conforms to the nucleus space created by the surgical removal of the diseased or damaged nucleus pulposus.
干预措施: PerQdisc (Device)
结局指标
主要结局
Clinical Composite Success
时间窗: 6 Months
Clinical composite success is defined as improvement in pain and absence of qualified safety events.
次要结局
- ODI(6 Months)
- VAS Back(6 Months)
研究者
研究点 (11)
Loading locations...
相似试验
招募中
不适用
MMA Embolization for Refractory Chronic MigraineNCT06735833Cerenovus, Part of DePuy Synthes Products, Inc.70
已完成
不适用
Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin InjuriesBurnsNCT02905435PolyNovo Biomaterials Pty Ltd.15
已完成
不适用
Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese SubjectsObesityNCT01207830ValenTx, Inc.10
招募中
不适用
A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional SeizuresFunctional SeizuresConvulsion, Non-EpilepticNCT05819268University of Alabama at Birmingham108
Unknown
不适用
Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary SyndromeRefractory Thrombus in Patients With Acute Coronary SyndromeNCT04692402Paul Ong51